logo
  Join        Login             Stock Quote

FDA OKs Expanded Use Of Bayer/Onyx Drug For Rare Gastrointestinal Tumor

 February 25, 2013 02:51 PM
 


(By Balachander) The U.S. Food and Drug Administration (FDA) has approved the expanded use of Bayer AG's drug Stivarga to treat a rare type of gastrointestinal tract cancer.

Stivarga, which was approved in September 2012 to treat colorectal cancer, is the third drug cleared by the U.S. health regulators to treat gastrointestinal stromal tumors (GIST).

Germany-based Bayer and South San Francisco, California-based Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) co-promote Stivarga - known as regorafenib - in the United States.

The FDA on Monday approved Stivarga for patients whose GIST cannot be surgically removed and no longer respond to other FDA-approved treatments Novartis' (NVS) Gleevec and Pfizer's (PFE) Sutent.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

GIST is a tumor in which cancerous cells form in the tissues of the gastrointestinal tract, part of the body's digestive system. According to the National Cancer Institute, an estimated 3,300 to 6,000 new cases of GIST occur yearly in the United States, most often in older adults.

According to the FDA, clincial study results showed patients taking Stivarga had a delay in tumor growth that was, on average, 3.9 months later than patients who were given a placebo.

[Related -Jobs Growth Tepid At Best]

The most common side effects reported in patients treated with Stivarga were weight loss, stomach pain, rash, fever, hand-foot syndrome, diarrhea, loss of appetite, high blood pressure and nausea.

Onyx shares inched 0.13 percent higher to trade at $78.40 at 2.38 pm ET on Monday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChicago Fed: Slowest US Growth In Nearly 3 Years

Economic activity in March slumped to the softest pace in 31 months, according to this morning’s update of read on...

article imageHas The Fed Already Lost?

Increasingly we live in a world of Now. Instantaneous access to digital real time data and news has simply read on...

article imageOn Being A Forced Seller in a Panic

No one wants to be a forced seller in a panic. So how does anyone get into that situation?  Two things: bad read on...

article imageECB's Quantitative Easing - QuitE Wrong

The eurozone has been doing fine without the ECB’s read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.